This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (543) Registered Report (516) Digital Biomarkers and Digital Phenotyping (178)

Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/42032, first published .
An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study

Authors of this article:

Shotaro Haji1 Author Orcid Image ;   Koji Fujita1 Author Orcid Image ;   Ryosuke Oki1 Author Orcid Image ;   Yusuke Osaki1 Author Orcid Image ;   Ryosuke Miyamoto1 Author Orcid Image ;   Hiroyuki Morino2 Author Orcid Image ;   Seiichi Nagano3, 4 Author Orcid Image ;   Naoki Atsuta5 Author Orcid Image ;   Yuki Kanazawa6 Author Orcid Image ;   Yuki Matsumoto7 Author Orcid Image ;   Atsuko Arisawa8 Author Orcid Image ;   Hisashi Kawai9 Author Orcid Image ;   Yasutaka Sato10 Author Orcid Image ;   Satoshi Sakaguchi10 Author Orcid Image ;   Kenta Yagi10 Author Orcid Image ;   Tatsuto Hamatani11 Author Orcid Image ;   Tatsuo Kagimura12 Author Orcid Image ;   Hiroaki Yanagawa10 Author Orcid Image ;   Hideki Mochizuki4 Author Orcid Image ;   Manabu Doyu5 Author Orcid Image ;   Gen Sobue13 Author Orcid Image ;   Masafumi Harada7 Author Orcid Image ;   Yuishin Izumi1 Author Orcid Image
Article Authors Cited by (2) Tweetations (2) Metrics

Journals

  1. Capriglia F, Burgess T, Bandmann O, Mortiboys H. Clinical Trial Highlights: Modulators of Mitochondrial Function. Journal of Parkinson's Disease 2023;13(6):851 View
  2. Hamatani T, Atsuta N, Sano F, Nakamura R, Hayashi Y, Sobue G. ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2024;25(3-4):388 View